Strategy for prevention of cancers of the esophagus

Annals of the New York Academy of Sciences

Volumn 1325, Issue 1, 2014, Pages 108-126

  Akiyama, Junichi ^a   Alexandre, Leo ^b,c   Baruah, Anushka ^d   Buttar, Navtej ^d   Chandra, Raghav ^d   Clark, Allan B ^b   Hart, Andrew R ^b,c   Hawk, Ernest ^e   Kandioler, Daniela ^f   Kappel, Sonja ^f   Krishnadath, Sheila K ^g   Sharma, Anamay ^d   Singh, Ishtpreet ^d   Straub, Danielle ^g   Triadafilopoulos, George ^h   Umar, Asad ^a   Wolf, Brigitte ^f  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h STANFORD UNIVERSITY   (United States)

Author keywords

Animal reflux inflammation models; Barrett's adenocarcinoma; Biomarkers; COXIBs, PPIs; Elofrnithine; OESO; Statins

Indexed keywords

BILE ACID; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PROTON PUMP INHIBITOR; PUTRESCINE; SPERMIDINE; SPERMINE; SULINDAC; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ABLATION THERAPY; ARTICLE; BARRETT ESOPHAGUS; CANCER PATIENT; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHROMOSOMAL INSTABILITY; EARLY CANCER; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; GENOMICS; HUMAN; INTESTINE METAPLASIA; MALIGNANT TRANSFORMATION; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); POLYAMINE METABOLISM; SECONDARY PREVENTION; ANIMAL; CELL TRANSFORMATION; ESOPHAGEAL NEOPLASMS; FRANCE; METABOLISM;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2 INHIBITORS; EFLORNITHINE; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PARIS; PROTON PUMP INHIBITORS;

EID: 84925060391     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12529     Document Type: Article

References (63)

1. Spechler, S.J., R.C. Fitzgerald & G.A. Prasad . 2010. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 38: 854-869.
2. Omura, N., H. Kashiwagi & G. Chen . 1999. Establishment of surgically induced chronic acid reflux esophagitis in rats. Scand. J. Gastroenterol. 34: 948-953.
3. Helsingen, N. 1960. Oesophagitis following total gastrectomy: a follow-up study on 9 patients 5 years or more after operation. Acta. Chir. Scand. 118: 190-201.
4. Levrat, M., R. Lambert & G. Kirshbaum . 1962. Esophagitis produced by reflux of duodenal contents in rats. Am. J. Dig. Dis. 7: 564-573.
5. Chen, X., G.Y. Yang & W.Y. Ding . 1999. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis. 20: 1801-1808.
6. Wang, X., H. Ouyang & Y. Yamamoto . 2011. Residual embryonic cells as precursors of a Barrett-like metaplasia. Cell 145: 1023-1035.
7. Quante, M., G. Bhagat & J.A. Abrams . 2012. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21: 36-51.
8. Xu, X.J., J. Locicero & E. Macri . 2000. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. J. Surg. Res. 88: 120-124.
9. DeMars, B.N.S. 2011. Novel in-vivo models of reflux injury and Barrett's esophagus. Abstract DDW. Abstract. Digestive Disease Week. Chicago, IL.
10. Bremner, C.G., V.P. Lynch & F.H. Ellis . 1970. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 68: 209-216.
11. Levine, D. M. et al. 2013. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat. Genet. 45: 1487-1493.
12. Vogelstein, B. et al. 2013. Cancer genome landscapes. Science 339: 1546-1558.
13. Bandla, S. et al. 2012. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann. Thorac. Surg. 93: 1101-1106.
14. Dulak, A. M. et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45: 478-486.
15. Chen, X. et al. 2002. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and α-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 23: 2095-2102.
16. Wang, K.K. & R.E. Sampliner . 2008. Updated guidelines 2008 for the diagnosis, surveillance, and therapy of Barrett's Esophagus. Am. J. Gastroenterol. 103: 788-797.
17. Garewal, H.S., R.E. Sampliner & M.B. Fennerty . 1992. Chemopreventive studies in Barrett's esophagus: a model premalignant lesion for esophageal adenocarcinoma. J. Natl. Cancer Inst. Monogr. 13: 51-54.
18. Sinicrope, F.A. et al. 2011. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prevent. Res. 4: 829-839.
19. Fong, L.Y., A.E. Pegg & P.N. Magee . 1998. α-Difluoromethylornithine inhibits N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in zinc-deficient rats: effects on esophageal cell proliferation and apoptosis. Cancer Res. 58: 5380-5388.
20. Wang, D.H. et al. 2010. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 138: 1810-1822.
21. Milano, F. et al. 2007. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132: 2412-2421.
22. Song, S. et al. 2007. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 56: 1512-1521.
23. Buttar, N.S. et al. 2002. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 94: 422-429.
24. Buttar, N.S. et al. 2002. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112.
25. Falk, G.W. et al. 2012. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 143: 917-926, e1.
26. O'Riordan, J.M. et al. 2005. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Gastroenterol. 100: 1257-1264.
27. Zhang, Q. et al. 2013. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology 146: 461-72.e6.
28. Rizvi, S. et al. 2010. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 70: 6787-6796.
29. Taniguchi, H. et al. 2005. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24: 7946-7952.
30. Wijnhoven, B.P. et al. 2010. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br. J. Surg. 97: 853-861.
31. Clemons, N.J., K.E.L. McColl & R.C. Fitzgerald . 2007. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133: 1198-1209.
32. Song, S. et al. 2009. Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin. Cancer Res. 15: 622-631.
33. Fitzgerald, R.C., R. Lascar & G. Triadafilopoulos . 2001. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther. 15: 269-276.
34. Gerson, L.B., K. Shetler & G. Triadafilopoulos . 2005. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig. Liver Dis. 37: 651-658.
35. Triadafilopoulos, G. 2000. Proton pump inhibitors for Barrett's oesophagus. Gut. 46: 144-146.
36. Kastelein, F., M.C. Spaander, E.W. Steyerberg, et al. 2013. ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 11: 382-388.
37. Lanas, A., J. Ortego, F. Sopeña, et al. 2007. Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus. Aliment Pharmacol. Ther. 26: 913-923.
38. Heath, E.I., M.I. Canto, S Piantadosi, et al. 2007. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Inst. 99: 545-557.
39. Rothwell, P.M., F.G. Fowkes, J.F. Belch, et al. 2011. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
40. Das, D., A.P. Chilton & J.A. Jankowski . 2009. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 181: 161-169.
41. Ogunwobi, O.O., & I.L. Beales . 2008. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am. J. Gastroenterol. 103: 825-837.
42. Sadaria, M.R., A.E. Reppert, J.A. Yu, et al. 2011. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J. Thorac. Cardiovasc. Surg. 142: 1152-1160.
43. Alexandre, L., A.B. Clark, E. Cheong, et al. 2012. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Alimentary Pharmacol. Therapeut. 36: 301-311.
44. Beales, I.L., I. Vardi & L. Dearman . 2012. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur. J. Gastroenterol. Hepatol. 24: 917-923.
45. Kantor, E.D., L. Onstad, P.L. Blount, et al. 2012. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 21: 456-461.
46. Kastelein, F., E.W. Steyerberg & M.J. Bruno . 2012. Immortal person-time bias in relation to the use of nonsteroidal anti-inflammatory drugs and statins in the prevention of esophageal cancer in patients with Barrett's esophagus reply. Gastroenterology 142: E21-E21.
47. Nguyen, D.M., P. Richardson & H.B. El-Serag . 2010. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 138: 2260-2266.
48. Nielsen, S.F., B.G. Nordestgaard & S.E. Bojesen . 2012. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367: 1792-1802.
49. Petitjean, A., E. Mathe, S. Kato, et al. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 28: 622-629.
50. Edlund, K., O. Larsson, A. Ameur, et al. 2012. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc. Nat. Acad. Sci. U.S.A. 109: 9551-9556.
51. Kern, S.E. & J.M. Winter . 2006. Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol. Therapy 5: 349-359.
52. th international p53 workshop, Stockholm, Schweden.
53. th international p53 workshop, Stockholm, Schweden.
54. Kappel, S., C. Bichler, B. Wolf, et al. 2008. for the Pancho Study Group. Turning the tables on surgical oncology: the Pancho trial unplugged. Eur. Surg. 40: 277-283.
55. Bhat, S., H.G. Coleman, F. Yousef, et al. 2011. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 103: 1049-1057.
56. Desai, T.K., K. Krishnan, N. Samala, et al. 2012. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 61: 970-976.
57. Hvid-Jensen, F., L. Pedersen, A.M. Drewes, et al. 2011. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365: 1375-1383.
58. Shaheen, N.J., M.A. Crosby, E.M. Bozymski & R.S. Sandler . 2000. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119: 333-338.
59. Wang, G.Q., C.C. Abnet, Q. Shen, et al. 2005. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 54: 187-192.
60. Spechler, S.J., P. Sharma, R.F. Souza, et al. 2011. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140: 1084-1091.
61. Shaheen, N.J., P. Sharma, B.F. Overholt, et al. 2009. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 360: 2277-2288.
62. Kadri, S.R., P. Lao-Sirieix, M. O'Donovan, et al. 2010. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 341: c4372.
63. Bird-Lieberman, E.L., AA Neves, P. Lao-Sirieix, et al. 2012. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18: 315-321.